ContraFect Has Received A Notice Of Allowance For Its U.S. Patent Application 16/629,916 Titled "Blood Component Potentiation Of Lytic Protein Anti-bacterial Activity And Methods And Uses Thereof"
Portfolio Pulse from Benzinga Newsdesk
ContraFect has received a notice of allowance for its U.S. patent application 16/629,916 titled 'Blood Component Potentiation Of Lytic Protein Anti-bacterial Activity And Methods And Uses Thereof'. This patent could potentially strengthen the company's intellectual property portfolio and provide a competitive edge in the market.
October 24, 2023 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The notice of allowance for ContraFect's U.S. patent application could potentially strengthen the company's intellectual property portfolio and provide a competitive edge in the market.
The notice of allowance for a patent application is a significant step towards the issuance of a patent. This could potentially strengthen ContraFect's intellectual property portfolio, providing a competitive edge in the market. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100